My take is this is seperate to the SubB2M program. EXO-NET is a platform technology used for isolating the relevant exosomes from the sample in question i.e., blood sample from a potential / suspected ovarian cancer patient. The assay UQ will be develop will to detect the relevant exosome marker in question.
Please also note that releasing news of signing a CRO for the SubB2M program is also no guarantee. Will they tech transfer a test developed in the iNOVIQ lab (ELISA / IHC) and if so, optimisation, validation and test readiness under a NATA / CAP accredited lab will need to be completed in roughly 12 - 18 months if we are to see an LDT launch in 2023. Importantly, are they manufacturing a research grade SubB2M product in the meantime in order to provide to the CRO to test in the developed assay?
- Forums
- ASX - By Stock
- Ann: INOVIQ & UQ Collaborate on Exosome-based Ovarian Cancer Test
My take is this is seperate to the SubB2M program. EXO-NET is a...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IIQ (ASX) to my watchlist
|
|||||
Last
56.5¢ |
Change
-0.005(0.88%) |
Mkt cap ! $59.61M |
Open | High | Low | Value | Volume |
56.0¢ | 60.0¢ | 55.5¢ | $78.24K | 138.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 20037 | 56.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
59.0¢ | 2003 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 20037 | 0.565 |
3 | 13000 | 0.560 |
3 | 14564 | 0.555 |
4 | 56637 | 0.550 |
2 | 14917 | 0.540 |
Price($) | Vol. | No. |
---|---|---|
0.590 | 2003 | 1 |
0.600 | 2023 | 2 |
0.610 | 2000 | 1 |
0.620 | 10000 | 1 |
0.625 | 1584 | 1 |
Last trade - 15.32pm 09/07/2024 (20 minute delay) ? |
Featured News
IIQ (ASX) Chart |